LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Начало・Списък с акции・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Затворен

СекторЗдравеопазване

38 2.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

37.21

Максимум

38.23

Ключови измерители
By Trading Economics
Приходи	-34M -248M
EPS	-1.13
Марж на печалбата	-74.379
Служители	700
EBITDA	-24M -261M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+85.52% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-258M 6.7B
Предишно отваряне	35.74
Предишно затваряне	38

Настроения в новините

By Acuity

34%

66%

88 / 372 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

40.67 / 41.96 Подкрепа & съпротива

REVOLUTION Medicines Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.08.2025 г., 22:51 ч. UTC

Печалби

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Rev $4.01B

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H Adj EPS $1.84

27.08.2025 г., 23:57 ч. UTC

Печалби

Trip.com Group 1H EPS $1.82

27.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27.08.2025 г., 23:39 ч. UTC

Печалби

Correction to Nvidia Earnings Article -- WSJ

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.08.2025 г., 22:59 ч. UTC

Пазарно говорене

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27.08.2025 г., 22:58 ч. UTC

Печалби

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27.08.2025 г., 22:57 ч. UTC

Печалби

South32 FY Free Cash Flow $192 Million

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Total Capital Expenditure $1.35 Billion

27.08.2025 г., 22:56 ч. UTC

Печалби

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27.08.2025 г., 22:55 ч. UTC

Печалби

South32 Net Cash $123 Million at June 30

27.08.2025 г., 22:54 ч. UTC

Печалби

South32: Focused on Maintaining Strong Operating Momentum

27.08.2025 г., 22:53 ч. UTC

Печалби

South32: $144 Million Remains to be Returned to Shareholders Under Program

27.08.2025 г., 22:53 ч. UTC

Печалби

South32 Extends Capital Management Program for 12 Months

27.08.2025 г., 22:52 ч. UTC

Печалби

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27.08.2025 г., 22:51 ч. UTC

Печалби

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27.08.2025 г., 22:50 ч. UTC

Печалби

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27.08.2025 г., 22:45 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27.08.2025 г., 22:44 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27.08.2025 г., 22:43 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27.08.2025 г., 22:43 ч. UTC

Печалби

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27.08.2025 г., 22:42 ч. UTC

Печалби

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources Net Debt $123 Million at June 30

27.08.2025 г., 22:40 ч. UTC

Печалби

Sandfire Resources FY Underlying Ebitda $527.7 Million

Сравнение с други в отрасъла

Ценова промяна

REVOLUTION Medicines Inc Прогноза

Ценова цел

By TipRanks

85.52% нагоре

12-месечна прогноза

Среден 69.16 USD 85.52%

Висок 80 USD

Нисък 37.91 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за REVOLUTION Medicines Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на REVOLUTION Medicines Inc през последните 3 месеца.

Техническа оценка

By Trading Central

40.67 / 41.96Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Настроение

By Acuity

88 / 372 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.